iiinova — where your digital self keeps evolving

Onco404 @onco404.bsky.social · 03/07/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #Oncology #GeriatricOncology #Oncogeriatrics #CancerCare #MedSky #OncSky #MedNews #Vocabulary

021

Onco404 @onco404.bsky.social · 27/06/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #Oncology #CancerAwareness #CancerCare #ParaneoplasticSyndrome #PNS #MedSky #OncSky #Vocabulary

021

Onco404 @onco404.bsky.social · 26/06/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #Oncology #MedSky #OncSky #CancerAwareness #InvestigationalNewDrug #IND #FDA #ClinicalTrials #Vocabulary

021

Onco404 @onco404.bsky.social · 30/05/2025

Multi-omics profiling is feasible, accelerates precision oncology, and improves outcomes for advanced melanoma. #Onco404 #Cancer #Kanser #PrecisionOncology #ClinicalTrials #TumorProfiling #MedSky #OncSky #ASCO2025

010

Onco404 @onco404.bsky.social · 30/05/2025

✅ PFS: 6.04 months (overall palliative), 5.35 months (≥3rd-line therapy). ☑️ Outperformed non-TuPro matched cohorts: 64.7% DCR (TuPro) vs. 23.5% (non-TuPro) in ≥3rd-line patients. ✅ Cost-effective: 1.8x higher than standard NGS but enabled highly individualized therapies.

110

Onco404 @onco404.bsky.social · 30/05/2025

📊 Key Findings ✅ In 75% of cases, TuPro-based data (beyond standard NGS) was judged useful by the MTB for treatment recommendations. 54 distinct markers informed decisions. ☑️ Beyond SOC patients (n=37) achieved 38% ORR and 54% DCR - remarkable for refractory cases!

110

Onco404 @onco404.bsky.social · 30/05/2025

The TuPro study used 9 #multiomics technologies (scRNA-seq, proteomics, etc.) to profile 116 #melanoma patients, generating >40,000 markers/sample in just 4 weeks. @natureportfolio.nature.com #Onco404 #Cancer #Kanser #PrecisionOncology #ClinicalTrials #TumorProfiling #MedSky #OncSky #ASCO2025

111

Onco404 @onco404.bsky.social · 30/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #MedSky #OncSky #CancerAwareness #CancerCare #Chemokine #ImmuneSystem #ImmuneResponse #TumorImmunity #Vocabulary

011

Onco404 @onco404.bsky.social · 29/05/2025

☑️ KRAS G12C ctDNA negativity at C1D8 → mPFS 7.26 vs 4.01 months ✅ ATM mutations reduced sotorasib benefit vs docetaxel (mPFS: 4.17 vs 8.25 months). 💡 These biomarkers enable precision patient selection and identify candidates for combination therapies. TTF-1 IHC may guide frontline decisions.

010

Onco404 @onco404.bsky.social · 29/05/2025

☑️ TTF-1 low vs TTF-1 high - ORR: 4.17% vs 42.1% ; mPFS: 2.76 vs 8.11 months (HR 0.23); mOS: 4.47 vs 16 months. ✅ Integration of NRF2 activation status and TTF-1 expression enabled robust partitioning of patients into favorable (~70%), intermediate (~13%) and poor (~17%) prognostic groups. #Onco404

110

Onco404 @onco404.bsky.social · 29/05/2025

📊 Key Findings ☑️ KEAP1 co-mutations were correlated with significantly shorter PFS and OS on sotorasib. ✅ NRF2 activation (often linked to KEAP1 mutations) was also associated with inferior outcomes. mPFS: 2.73 vs 7.75 months (NRF2 low) #Onco404 #Cancer #Kanser #AkciğerKanseri #MedSky #OncSky

110

Onco404 @onco404.bsky.social · 29/05/2025

This integrated analysis of CodeBreaK 100 & 200 trials delves into biomarkers influencing sotorasib efficacy in KRAS G12C-mutated NSCLC. #NatureMedicine #Onco404 #Cancer #Kanser #LungCancer #Sotorasib #NSCLC #Biomarkers #PrecisionOncology #KRAS #TTF1 #KEAP1 #NRF2 #NFE2L2 #MedSky #OncSky

111

Onco404 @onco404.bsky.social · 29/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #CancerAwareness #Cytokine #ImmuneSystem #CancerCare #Inflammation #MedSky #OncSky #Vocabulary

011

Onco404 @onco404.bsky.social · 28/05/2025

❌ No significant differences in quality of life, feeling "heard/understood," or late hospice referrals. ✅ This scalable EHR-based strategy addressed clinician barriers, increased PC access without overburdening workflows, and offers a pragmatic solution for resource-limited settings. #Onco404

010

Onco404 @onco404.bsky.social · 28/05/2025

📊 Key Findings ✅ 43.9% (intervention) vs. 8.3% (control) completed PC consults (adjusted OR: 8.9) ⤴️ ☑️ Systemic therapy within 14 days of death was lower in the intervention group (6.5%) compared to control (16.1%; AOR 0.3). #Onco404 #Cancer #Kanser #Hospice #PalliativeCare #MedSky #OncSky

110

Onco404 @onco404.bsky.social · 28/05/2025

A cluster randomized trial tested if algorithm-based EHR defaults with accountable justification could increase specialty palliative care (PC) consultations. @JAMANetworkOpen #JAMA #Onco404 #Cancer #Kanser #Hospice #PalliativeCare #SupportiveCare #MedSky #OncSky #Healthcare #DigitalHealth

111

Onco404 @onco404.bsky.social · 28/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #CancerAwareness #Hospice #YaşamSonuBakımı #PalliativeCare #PalyatifBakım #QoL #MedSky #OncSky #Vocabulary

011

Onco404 @onco404.bsky.social · 27/05/2025

Timely and comprehensive HRQoL data is vital for integrating patient experiences into clinical and regulatory decision-making. #Onco404 #Cancer #Kanser #Oncology #ClinicalTrials #FDA #QoL #HRQoL #MedSky #OncSky #PatientReportedOutcomes

010

Onco404 @onco404.bsky.social · 27/05/2025

📊 HRQoL improved in 43% of trials but worsened in 4%, all linked to SEP-based approvals ⚠️ Reporting hasn’t improved since 2015. Delays mean doctors and patients often wait 6+ months ⚠️ Median latency for reporting was 1.1 months post-approval, but a quarter took over a year #Onco404 #Cancer #Kanser

110

Onco404 @onco404.bsky.social · 27/05/2025

📊 Key Findings 📉 50% of trials reported HRQoL data, but only 42% had it available by FDA approval. 📉 79% of approvals relied on surrogate endpoints, yet only 18% of these showed improved HRQoL. 💊 Trials with survival (OS) endpoints: 70% reported HRQoL vs. 45% for SEPs. #Onco404 #Cancer #Kanser

110

Onco404 @onco404.bsky.social · 27/05/2025

A new study analyzed 233 trials associated with 207 FDA approvals (2015–2020) and found alarming gaps in health-related quality of life (HRQoL) reporting. #BMJ #BMJOncology #Onco404 #Cancer #Kanser #Oncology #ClinicalTrials #FDA #QoL #HRQoL #MedSky #OncSky #PatientReportedOutcomes

111

Onco404 @onco404.bsky.social · 27/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #MedSky #OncSky #PatientCenteredCare #CancerCare #QualityOfLife #QoL #PatientReportedOutcomes #PROs #Vocabulary

011

Onco404 @onco404.bsky.social · 26/05/2025

☑️ Trabectedin showed a higher frequency of grade ≥3 adverse events (AEs), serious AEs, and serious adverse drug reactions. Trabectedin did not improve survival vs. standard chemo and had a worse safety profile. No subgroup (BRCA status, prior PARPi use) benefited more from trabectedin. #Onco404

010

Onco404 @onco404.bsky.social · 26/05/2025

📊 Key Findings ✅ Median overall survival (OS): 15.8 months (arm A: trabectedin) vs. 17.9 months (arm B: control). ☑️ Median progression-free survival (PFS): 4.9 vs. 4.4 months. ✅ ORR was 17.1% (arm A) vs. 21.4% (arm B), with comparable median DoR (5.62 vs. 5.66 months). #Onco404 #MedSky #OncSky

110

Onco404 @onco404.bsky.social · 26/05/2025

The phase III MITO-23 trial compared trabectedin monotherapy to physician’s choice chemo in 244 patients with BRCA-mutated or BRCAness recurrent ovarian cancer. @ascocancer.bsky.social #JCO #ASCO #Onco404 #Cancer #Kanser #OvarianCancer #MedSky #OncSky #BRCA #BRCAness #Trabectedin #ClinicalTrials

120

Onco404 @onco404.bsky.social · 26/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #MedSky #OncSky #BRCAness #HRD #BRCA1 #BRCA2 #PlatinumChemotherapy #PARPInhibitor #TargetedTherapy #Vocabulary

021

Onco404 @onco404.bsky.social · 26/05/2025

📌 "OncoTerm - Word of the Day" - WEEKLY DIGEST (May 19-25)👋 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #OncoTerm #Oncology #Cancer #Kanser #CancerAwareness #Healthcare #FightCancer #MedSky #OncSky #Vocabulary

011

Onco404 @onco404.bsky.social · 26/05/2025

📌 “OncoTerm - Günün Kelimesi” - HAFTALIK ÖZET (19-25 Mayıs) 👋 Kansere karşı mücadelede kendimizi bilgiyle güçlendirmek için temel terimleri açıklarken bize katılın. #Onco404 #OncoTerm #Oncology #Cancer #Kanser #CancerAwareness #Healthcare #FightCancer #Vocabulary

011

Onco404 @onco404.bsky.social · 25/05/2025

Encorafenib + binimetinib shows strong efficacy, especially in treatment-naïve patients. Genomic-guided triplet therapies need refinement, resistance mechanisms are complex! 🧬 #Onco404 #Cancer #Kanser #Melanoma #TargetedTherapy #ClinicalTrials #BRAF #PrecisionMedicine #MedSky #OncSky

010

Onco404 @onco404.bsky.social · 25/05/2025

2️⃣ Part II (Triplet Therapy, n=58) ✅ Adding a third agent (ribociclib, capmatinib, etc.) post-progression lacked efficacy (response rates: 2.6% to 0% 🚫), emphasizing the challenge of overcoming resistance. ✅ Safety: Adverse events were manageable and consistent with known safety profiles. #Onco404

110

Onco404 @onco404.bsky.social · 25/05/2025

📊 Key Findings 1️⃣ Part I (Encorafenib + Binimetinib) ✅ BRAFi/MEKi-naïve (n=75): Confirmed ORR 73.3% (95% CI, 61.9-82.9). Median PFS 11.1 months. ✅ BRAFi/MEKi-pretreated (n=83): Confirmed ORR 25.3% (95% CI, 16.4-36.0). Median PFS 3.3 months. #Onco404 #Cancer #Kanser #Melanoma #MedSky #OncSky

110

Onco404 @onco404.bsky.social · 25/05/2025

This phase II study assessed encorafenib + binimetinib (BRAFi/MEKi), followed by the addition of a third targeted agent based on genomic alterations at progression @theaacr.bsky.social #CCR #Onco404 #Cancer #Kanser #Melanoma #TargetedTherapy #ClinicalTrials #BRAF #PrecisionMedicine #MedSky #OncSky

121

Onco404 @onco404.bsky.social · 25/05/2025

This May, Onco404 honors every unique journey touched by melanoma and skin cancer 🏅 Every step forward, every shared story, fuels our collective hope 🕊️ You are not alone 🖤 #Onco404 #Cancer #Kanser #Melanoma #MelanomaAwarenessMonth #SkinCancerAwarenessMonth #Hope #MedSky #OncSky

011

Onco404 @onco404.bsky.social · 25/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #CancerAwareness #CancerPrevalence #CancerPrevention #CancerScreening #PublicHealth #Healthcare #Vocabulary

011

Onco404 @onco404.bsky.social · 24/05/2025

With mature OS data, ripretinib demonstrates comparable survival to sunitinib with a better long-term safety profile in second-line advanced GIST. #Onco404 #Cancer #Kanser #GIST #Ripretinib #Sunitinib #ClinicalTrials #MedSky #OncSky

010

Onco404 @onco404.bsky.social · 24/05/2025

✅ Second PFS: Similar between arms (7.7 vs. 7.4 months; HR 1.03), showing no negative impact from prior ripretinib. ☑️ Consistent with primary analysis, ripretinib maintained a more favorable safety profile. Fewer grade 3/4 trAEs with ripretinib (43%) vs. sunitinib (67%). #Onco404 #Cancer #MedSky

110

Onco404 @onco404.bsky.social · 24/05/2025

📊 Key Findings ✅ Median OS (overall population): 35.5 vs. 31.5 months (ripretinib vs. sunitinib; HR 0.86). ☑️ KIT exon 11 subgroup: 35.5 vs. 32.8 months (HR 0.98). #Onco404 #Cancer #Kanser #GIST #Ripretinib #Sunitinib #ClinicalTrials #MedSky #OncSky

110

Onco404 @onco404.bsky.social · 24/05/2025

The final analysis of the INTRIGUE phase III trial reveals ripretinib and sunitinib show comparable overall survival in advanced GIST patients post-imatinib. @ascocancer.bsky.social #JCO #ASCO #Onco404 #Cancer #Kanser #GIST #Ripretinib #Sunitinib #ClinicalTrials #MedSky #OncSky

120

Onco404 @onco404.bsky.social · 24/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer #Onco404 #Cancer #Kanser #CancerAwareness #Incidence #CancerIncidence #CancerPrevention #CancerScreening #PublicHealth #MedSky #Vocabulary

011

Onco404 @onco404.bsky.social · 23/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #TP53 #LiFraumeniSyndrome #CancerPrevention #Sarcoma #BreastCancer #Leukemia #BrainTumors #ACC #Vocabulary

011

Onco404 @onco404.bsky.social · 22/05/2025

Lynch syndrome carriers face up to 80% lifetime CRC risk! The ongoing CAPP3 trial is exploring optimal aspirin doses (100 mg vs 300 mg vs 600 mg). #Onco404 #Cancer #Kanser #ClinicalTrials #LynchSyndrome #ColorectalCancer #EndometrialCancer #Aspirin #CancerPrevention #MedSky #OncSky

020

Onco404 @onco404.bsky.social · 22/05/2025

☑️ Number Needed to Treat (NNT) = 24 to prevent 1 CRC case. ✅ Protection emerged ~5 years post-intervention and persisted for decades! 🌟 ☑️ While non-CRC Lynch cancers showed no significant effect, endometrial cancer hinted at benefit (7 vs. 17 cases). #Onco404 #Cancer #Kanser #MedSky #OncSky

110

Onco404 @onco404.bsky.social · 22/05/2025

📊 Key Findings ✅ 861 pts (427 aspirin vs 434 placebo): 9% of aspirin group developed CRC vs. 13% on placebo. ☑️ Intention-to-treat (ITT): Aspirin significantly reduced CRC risk (HR 0.65). ✅ Per-protocol analysis (2+ years adherence): Even stronger reduction, 44% lower risk (HR 0.56). #Onco404

110

Onco404 @onco404.bsky.social · 22/05/2025

The CAPP2 trial (long-term follow-up) reveals that 600 mg aspirin daily for ≥2 years cuts colorectal cancer (CRC) risk in Lynch syndrome patients by 35% 💊 #Lancet #Onco404 #Cancer #Kanser #ClinicalTrials #LynchSyndrome #ColorectalCancer #EndometrialCancer #Aspirin #CancerPrevention #MedSky #OncSky

121

Onco404 @onco404.bsky.social · 22/05/2025

📌 OncoTerm - Word of the Day! 👋 OncoTerm - Günün Kelimesi! 📌 Join us as we break down key terms to empower ourselves with knowledge in the fight against cancer. #Onco404 #Cancer #Kanser #CancerAwareness #LynchSyndrome #RiskFactor #ColorectalCancer #EndometrialCancer #MedSky #OncSky #Vocabulary

011

Onco404 @onco404.bsky.social · 21/05/2025

Behavioral risk factors remain the largest contributors globally. However, the rising burden from metabolic risks demands urgent attention. Tailored, context-specific policies are crucial to reduce exposure and decrease cancer mortality worldwide. #Onco404 #Cancer #Kanser #MedSky #OncSky

010

Onco404 @onco404.bsky.social · 21/05/2025

📍Gender & Regional Gaps ☑️ Men: 50.6% of cancer deaths tied to risks vs. 36.3% for women. ✅ Low SDI areas: Unsafe sex 🌐 ranks #2 risk; high SDI mirrors global trends. ☑️ Metabolic risks surged globally, with low-middle SDI nations hardest hit. #Onco404 #Cancer #Kanser #MedSky #OncSky #PublicHealth

110

Onco404 @onco404.bsky.social · 21/05/2025

📊 Key Findings 🚬 Smoking: Leading cause, contributing to 33.9% of male cancer disability-adjusted life-years (DALYs). 🍷 Alcohol use: Major driver, especially in high socio-demographic index (SDI) regions. 📈 High BMI: Fastest-growing risk, with 34.7% rise in deaths (2010–2019). #Onco404 #Cancer

110

Onco404 @onco404.bsky.social · 21/05/2025

A 2019 Global Burden of Disease Study reveals 44.4% of cancer deaths (4.45M) were linked to modifiable risk factors. @thelancet.com #Onco404 #Cancer #Kanser #PublicHealth #HalkSağlığı #CancerPrevention #GlobalHealth #Healthcare #RiskFactors #MedSky #OncSky

110